Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of ...

"An appealing feature of [intermittent fasting] is that dieters do not have to focus on counting calories and restricting ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its platform ...

The Trump administration has fired staff who were working on the Food and Drug Administration's bird flu response as part of ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...